View ValuationNeoPharm 将来の成長Future 基準チェック /16NeoPharm利益と収益がそれぞれ年間14.1%と14.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に16.3% 13.4%なると予測されています。主要情報14.1%収益成長率13.42%EPS成長率Personal Products 収益成長30.3%収益成長率14.8%将来の株主資本利益率16.30%アナリストカバレッジLow最終更新日18 Jun 2026今後の成長に関する最新情報Price Target Changed • Aug 14Price target increased to ₩46,333Up from ₩42,500, the current price target is an average from 3 analysts. New target price is 50% above last closing price of ₩30,950. Stock is down 4.0% over the past year.Major Estimate Revision • Nov 11Analysts lower EPS estimates to ₩2,091The 2020 consensus revenue estimate was lowered from ₩85.3m to ₩82.0m. Earning per share (EPS) estimate was also lowered from ₩2,326 to ₩2,091 for the same period. Net income is expected to shrink by 5.9% next year compared to 61% growth forecast for the Personal Products industry in South Korea . The consensus price target was lowered from ₩44,250 to ₩42,500. Share price is up 5.9% to ₩28,850 over the past week.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩18,240, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 12x in the Personal Products industry in South Korea. Total returns to shareholders of 65% over the past three years.Reported Earnings • Mar 21Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₩1,779 (up from ₩1,475 in FY 2024). Revenue: ₩132.2b (up 11% from FY 2024). Net income: ₩27.8b (up 21% from FY 2024). Profit margin: 21% (up from 19% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 04NeoPharm CO., LTD., Annual General Meeting, Mar 24, 2026NeoPharm CO., LTD., Annual General Meeting, Mar 24, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 309-8, techno 2-ro, yuseong-gu, daejeon South Korea分析記事 • Jan 22NeoPharm (KOSDAQ:092730) Hasn't Managed To Accelerate Its ReturnsIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Upcoming Dividend • Dec 22Upcoming dividend of ₩600 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 09 April 2026. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 3.1%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.8%).Declared Dividend • Nov 08Dividend of ₩600 announcedDividend of ₩600 is the same as last year. Ex-date: 29th December 2025 Payment date: 9th April 2026 Dividend yield will be 3.6%, which is higher than the industry average of 1.2%. Sustainability & Growth Dividend is well covered by both earnings (37% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 11% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Nov 07NeoPharm CO., LTD. announces Annual dividend, payable on April 09, 2026NeoPharm CO., LTD. announced Annual dividend of KRW 600.0000 per share payable on April 09, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Sep 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩21,700, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 156% over the past three years.Buy Or Sell Opportunity • Jul 25Now 20% undervaluedOver the last 90 days, the stock has risen 42% to ₩18,790. The fair value is estimated to be ₩23,545, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 12%.分析記事 • Jul 23NeoPharm CO., LTD.'s (KOSDAQ:092730) 37% Price Boost Is Out Of Tune With EarningsNeoPharm CO., LTD. ( KOSDAQ:092730 ) shares have continued their recent momentum with a 37% gain in the last month...Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩19,640, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 116% over the past three years.Reported Earnings • Mar 20Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: ₩1,475 (down from ₩1,484 in FY 2023). Revenue: ₩119.0b (up 23% from FY 2023). Net income: ₩23.1b (flat on FY 2023). Profit margin: 19% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 1.8%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 05NeoPharm CO., LTD., Annual General Meeting, Mar 26, 2025NeoPharm CO., LTD., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 309-8, techno 2-ro, yuseong-gu, daejeon South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩750 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 3.2%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).New Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.分析記事 • Nov 20We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising EarningsThe recent earnings posted by NeoPharm CO., LTD. ( KOSDAQ:092730 ) were solid, but the stock didn't move as much as we...分析記事 • Nov 13The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire ConfidenceIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...New Risk • Oct 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩104.8b (US$76.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₩104.8b market cap, or US$76.0m).Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩26,350, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Personal Products industry in South Korea. Total returns to shareholders of 5.6% over the past three years.分析記事 • Sep 13NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some InvestorsWith a price-to-earnings (or "P/E") ratio of 7.9x NeoPharm CO., LTD. ( KOSDAQ:092730 ) may be sending bullish signals...Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: ₩752 (vs ₩699 in 2Q 2023)Second quarter 2024 results: EPS: ₩752 (up from ₩699 in 2Q 2023). Revenue: ₩30.6b (up 25% from 2Q 2023). Net income: ₩5.88b (up 7.6% from 2Q 2023). Profit margin: 19% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.分析記事 • Aug 07NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return TrendsWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Jun 13NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than ExpectedThe NeoPharm CO., LTD. ( KOSDAQ:092730 ) share price has done very well over the last month, posting an excellent gain...分析記事 • Apr 24Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share PriceNeoPharm CO., LTD.'s ( KOSDAQ:092730 ) price-to-earnings (or "P/E") ratio of 8.7x might make it look like a buy right...分析記事 • Mar 25NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They SeemNeoPharm CO., LTD.'s ( KOSDAQ:092730 ) robust earnings report didn't manage to move the market for its stock. Our...Reported Earnings • Mar 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: ₩2,968 (up from ₩2,177 in FY 2022). Revenue: ₩97.1b (up 14% from FY 2022). Net income: ₩23.2b (up 36% from FY 2022). Profit margin: 24% (up from 20% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.2%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Upcoming Dividend • Dec 20Upcoming dividend of ₩700 per share at 2.9% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.2%).Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,750, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 30x in the Personal Products industry in South Korea. Total loss to shareholders of 22% over the past three years.Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩20,150, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 33x in the Personal Products industry in South Korea. Total loss to shareholders of 33% over the past three years.Buying Opportunity • Apr 10Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be ₩22,737, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 5.4%.Reported Earnings • Mar 16Full year 2022 earnings released: EPS: ₩2,177 (vs ₩2,265 in FY 2021)Full year 2022 results: EPS: ₩2,177 (down from ₩2,265 in FY 2021). Revenue: ₩85.0b (down 3.3% from FY 2021). Net income: ₩17.0b (down 3.9% from FY 2021). Profit margin: 20% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year and the company’s share price has also fallen by 5% per year.Buying Opportunity • Dec 28Now 20% undervaluedOver the last 90 days, the stock is up 11%. The fair value is estimated to be ₩23,468, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has declined by 4.9%.Upcoming Dividend • Dec 21Upcoming dividend of ₩700 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.3%).Reported Earnings • Mar 16Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: EPS: ₩2,265 (down from ₩2,318 in FY 2020). Revenue: ₩87.9b (up 7.7% from FY 2020). Net income: ₩17.7b (down 2.3% from FY 2020). Profit margin: 20% (down from 22% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 8.6%, compared to a 8.8% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Buying Opportunity • Feb 24Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 1.6%. The fair value is estimated to be ₩31,950, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% per annum over the last 3 years. Earnings per share has grown by 3.1% per annum over the last 3 years.Upcoming Dividend • Dec 22Upcoming dividend of ₩650 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.7%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Price Target Changed • Aug 14Price target increased to ₩46,333Up from ₩42,500, the current price target is an average from 3 analysts. New target price is 50% above last closing price of ₩30,950. Stock is down 4.0% over the past year.分析記事 • Mar 28Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩2,318 (vs ₩2,570 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: ₩81.6b (down 1.9% from FY 2019). Net income: ₩18.1b (down 5.8% from FY 2019). Profit margin: 22% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.分析記事 • Mar 15What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?While NeoPharm CO., LTD. ( KOSDAQ:092730 ) might not be the most widely known stock at the moment, it saw a decent...分析記事 • Mar 02How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?While not a mind-blowing move, it is good to see that the NeoPharm CO., LTD. ( KOSDAQ:092730 ) share price has gained...分析記事 • Feb 18We're Watching These Trends At NeoPharm (KOSDAQ:092730)What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...分析記事 • Feb 08We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory EarningsIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...分析記事 • Jan 26NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend StockCould NeoPharm CO., LTD. ( KOSDAQ:092730 ) be an attractive dividend share to own for the long haul? Investors are...分析記事 • Jan 15An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% UndervaluedDoes the January share price for NeoPharm CO., LTD. ( KOSDAQ:092730 ) reflect what it's really worth? Today, we will...Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩34,000, the stock is trading at a trailing P/E ratio of 14.2x, up from the previous P/E ratio of 12.1x. This compares to an average P/E of 36x in the Personal Products industry in South Korea. Total return to shareholders over the past three years is a loss of 28%.Is New 90 Day High Low • Jan 08New 90-day high: ₩29,500The company is up 2.0% from its price of ₩28,800 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩49,095 per share.分析記事 • Jan 04Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?It is hard to get excited after looking at NeoPharm's (KOSDAQ:092730) recent performance, when its stock has declined...分析記事 • Dec 24NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend SoonReaders hoping to buy NeoPharm CO., LTD. ( KOSDAQ:092730 ) for its dividend will need to make their move shortly, as...Upcoming Dividend • Dec 22Upcoming Dividend of ₩750 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.7% is in the top quartile of South Korean dividend payers (2.6%), and it is higher than industry peers (0.6%).分析記事 • Dec 15What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?NeoPharm CO., LTD. ( KOSDAQ:092730 ), is not the largest company out there, but it maintained its current share price...分析記事 • Dec 04Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Nov 23Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...Major Estimate Revision • Nov 11Analysts lower EPS estimates to ₩2,091The 2020 consensus revenue estimate was lowered from ₩85.3m to ₩82.0m. Earning per share (EPS) estimate was also lowered from ₩2,326 to ₩2,091 for the same period. Net income is expected to shrink by 5.9% next year compared to 61% growth forecast for the Personal Products industry in South Korea . The consensus price target was lowered from ₩44,250 to ₩42,500. Share price is up 5.9% to ₩28,850 over the past week.Is New 90 Day High Low • Sep 24New 90-day low: ₩27,250The company is down 18% from its price of ₩33,150 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩47,836 per share.業績と収益の成長予測KOSDAQ:A092730 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2027178,00037,000N/A38,000112/31/2026154,00033,000N/A35,000112/31/2025132,18427,82327,18428,410N/A9/30/2025129,81427,79728,67029,915N/A6/30/2025123,76825,27424,97227,060N/A3/31/2025122,40724,09023,01025,094N/A12/31/2024119,01423,06515,55418,631N/A9/30/2024112,20022,334-6,38216,167N/A6/30/2024107,85822,929-3,94117,678N/A3/31/2024101,73522,516-1,80820,105N/A12/31/202397,10523,2132,43523,263N/A9/30/202392,27120,73322,96724,024N/A6/30/202389,29219,78120,19921,423N/A3/31/202386,27218,91218,96619,685N/A12/31/202285,03317,02717,35418,161N/A9/30/202286,80518,24517,37318,071N/A6/30/202287,42417,37017,80918,258N/A3/31/202287,32116,90518,77519,267N/A12/31/202187,93117,71321,20321,681N/A9/30/202186,80218,20720,32020,881N/A6/30/202185,27518,05921,19021,766N/A3/31/202185,28718,47418,83719,464N/A12/31/202081,62518,13116,34317,074N/A9/30/202081,41318,73411,30917,364N/A6/30/202082,61819,93512,02818,544N/A3/31/202082,68019,90116,90924,255N/A12/31/201983,24019,24512,03019,224N/A9/30/201979,61118,002N/A17,190N/A6/30/201974,86316,675N/A15,234N/A3/31/201969,50015,795N/A12,149N/A12/31/201866,27515,370N/A16,179N/A9/30/201863,14313,682N/A13,893N/A6/30/201860,23613,105N/A14,629N/A3/31/201857,17512,514N/A12,814N/A12/31/201753,63411,559N/A10,646N/A9/30/201749,7659,814N/A10,212N/A6/30/201746,7399,365N/A9,866N/A3/31/201743,1648,096N/A9,548N/A12/31/201642,3697,742N/A9,157N/A9/30/201643,0975,955N/A8,664N/A6/30/201641,9995,419N/A6,471N/A12/31/201535,9653,407N/A6,095N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A092730の予測収益成長率 (年間14.1% ) は 貯蓄率 ( 3.1% ) を上回っています。収益対市場: A092730の収益 ( 14.1% ) KR市場 ( 32% ) よりも低い成長が予測されています。高成長収益: A092730の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: A092730の収益 ( 14.8% ) KR市場 ( 16.1% ) よりも低い成長が予測されています。高い収益成長: A092730の収益 ( 14.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A092730の 自己資本利益率 は、3年後には低くなると予測されています ( 16.3 %)。成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/14 13:41終値2026/07/14 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NeoPharm CO., LTD. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Jiseon AnDAOL Investment & Securities Co., Ltd.Byung-Ki KimHanwha Investment & Securities Co., Ltd.Seung Wook LeeHanwha Investment & Securities Co., Ltd.4 その他のアナリストを表示
Price Target Changed • Aug 14Price target increased to ₩46,333Up from ₩42,500, the current price target is an average from 3 analysts. New target price is 50% above last closing price of ₩30,950. Stock is down 4.0% over the past year.
Major Estimate Revision • Nov 11Analysts lower EPS estimates to ₩2,091The 2020 consensus revenue estimate was lowered from ₩85.3m to ₩82.0m. Earning per share (EPS) estimate was also lowered from ₩2,326 to ₩2,091 for the same period. Net income is expected to shrink by 5.9% next year compared to 61% growth forecast for the Personal Products industry in South Korea . The consensus price target was lowered from ₩44,250 to ₩42,500. Share price is up 5.9% to ₩28,850 over the past week.
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩18,240, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 12x in the Personal Products industry in South Korea. Total returns to shareholders of 65% over the past three years.
Reported Earnings • Mar 21Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₩1,779 (up from ₩1,475 in FY 2024). Revenue: ₩132.2b (up 11% from FY 2024). Net income: ₩27.8b (up 21% from FY 2024). Profit margin: 21% (up from 19% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 20%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 04NeoPharm CO., LTD., Annual General Meeting, Mar 24, 2026NeoPharm CO., LTD., Annual General Meeting, Mar 24, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 309-8, techno 2-ro, yuseong-gu, daejeon South Korea
分析記事 • Jan 22NeoPharm (KOSDAQ:092730) Hasn't Managed To Accelerate Its ReturnsIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Upcoming Dividend • Dec 22Upcoming dividend of ₩600 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 09 April 2026. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 3.1%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.8%).
Declared Dividend • Nov 08Dividend of ₩600 announcedDividend of ₩600 is the same as last year. Ex-date: 29th December 2025 Payment date: 9th April 2026 Dividend yield will be 3.6%, which is higher than the industry average of 1.2%. Sustainability & Growth Dividend is well covered by both earnings (37% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 11% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 07NeoPharm CO., LTD. announces Annual dividend, payable on April 09, 2026NeoPharm CO., LTD. announced Annual dividend of KRW 600.0000 per share payable on April 09, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Sep 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Sep 09Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩21,700, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 156% over the past three years.
Buy Or Sell Opportunity • Jul 25Now 20% undervaluedOver the last 90 days, the stock has risen 42% to ₩18,790. The fair value is estimated to be ₩23,545, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 12%.
分析記事 • Jul 23NeoPharm CO., LTD.'s (KOSDAQ:092730) 37% Price Boost Is Out Of Tune With EarningsNeoPharm CO., LTD. ( KOSDAQ:092730 ) shares have continued their recent momentum with a 37% gain in the last month...
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩19,640, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 116% over the past three years.
Reported Earnings • Mar 20Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: EPS: ₩1,475 (down from ₩1,484 in FY 2023). Revenue: ₩119.0b (up 23% from FY 2023). Net income: ₩23.1b (flat on FY 2023). Profit margin: 19% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates by 1.8%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 05NeoPharm CO., LTD., Annual General Meeting, Mar 26, 2025NeoPharm CO., LTD., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 309-8, techno 2-ro, yuseong-gu, daejeon South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩750 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 09 April 2025. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 3.2%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
New Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. This is currently the only risk that has been identified for the company.
分析記事 • Nov 20We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising EarningsThe recent earnings posted by NeoPharm CO., LTD. ( KOSDAQ:092730 ) were solid, but the stock didn't move as much as we...
分析記事 • Nov 13The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire ConfidenceIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
New Risk • Oct 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩104.8b (US$76.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (₩104.8b market cap, or US$76.0m).
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩26,350, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 13x in the Personal Products industry in South Korea. Total returns to shareholders of 5.6% over the past three years.
分析記事 • Sep 13NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some InvestorsWith a price-to-earnings (or "P/E") ratio of 7.9x NeoPharm CO., LTD. ( KOSDAQ:092730 ) may be sending bullish signals...
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: ₩752 (vs ₩699 in 2Q 2023)Second quarter 2024 results: EPS: ₩752 (up from ₩699 in 2Q 2023). Revenue: ₩30.6b (up 25% from 2Q 2023). Net income: ₩5.88b (up 7.6% from 2Q 2023). Profit margin: 19% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
分析記事 • Aug 07NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return TrendsWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
分析記事 • Jun 13NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than ExpectedThe NeoPharm CO., LTD. ( KOSDAQ:092730 ) share price has done very well over the last month, posting an excellent gain...
分析記事 • Apr 24Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share PriceNeoPharm CO., LTD.'s ( KOSDAQ:092730 ) price-to-earnings (or "P/E") ratio of 8.7x might make it look like a buy right...
分析記事 • Mar 25NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They SeemNeoPharm CO., LTD.'s ( KOSDAQ:092730 ) robust earnings report didn't manage to move the market for its stock. Our...
Reported Earnings • Mar 22Full year 2023 earnings: EPS exceeds analyst expectationsFull year 2023 results: EPS: ₩2,968 (up from ₩2,177 in FY 2022). Revenue: ₩97.1b (up 14% from FY 2022). Net income: ₩23.2b (up 36% from FY 2022). Profit margin: 24% (up from 20% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.2%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Personal Products industry in South Korea. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 20Upcoming dividend of ₩700 per share at 2.9% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.2%).
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,750, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 30x in the Personal Products industry in South Korea. Total loss to shareholders of 22% over the past three years.
Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩20,150, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 33x in the Personal Products industry in South Korea. Total loss to shareholders of 33% over the past three years.
Buying Opportunity • Apr 10Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be ₩22,737, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 5.4%.
Reported Earnings • Mar 16Full year 2022 earnings released: EPS: ₩2,177 (vs ₩2,265 in FY 2021)Full year 2022 results: EPS: ₩2,177 (down from ₩2,265 in FY 2021). Revenue: ₩85.0b (down 3.3% from FY 2021). Net income: ₩17.0b (down 3.9% from FY 2021). Profit margin: 20% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year and the company’s share price has also fallen by 5% per year.
Buying Opportunity • Dec 28Now 20% undervaluedOver the last 90 days, the stock is up 11%. The fair value is estimated to be ₩23,468, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has declined by 4.9%.
Upcoming Dividend • Dec 21Upcoming dividend of ₩700 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.3%).
Reported Earnings • Mar 16Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: EPS: ₩2,265 (down from ₩2,318 in FY 2020). Revenue: ₩87.9b (up 7.7% from FY 2020). Net income: ₩17.7b (down 2.3% from FY 2020). Profit margin: 20% (down from 22% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 8.6%, compared to a 8.8% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Buying Opportunity • Feb 24Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 1.6%. The fair value is estimated to be ₩31,950, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% per annum over the last 3 years. Earnings per share has grown by 3.1% per annum over the last 3 years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩650 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.7%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Price Target Changed • Aug 14Price target increased to ₩46,333Up from ₩42,500, the current price target is an average from 3 analysts. New target price is 50% above last closing price of ₩30,950. Stock is down 4.0% over the past year.
分析記事 • Mar 28Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩2,318 (vs ₩2,570 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: ₩81.6b (down 1.9% from FY 2019). Net income: ₩18.1b (down 5.8% from FY 2019). Profit margin: 22% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
分析記事 • Mar 15What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?While NeoPharm CO., LTD. ( KOSDAQ:092730 ) might not be the most widely known stock at the moment, it saw a decent...
分析記事 • Mar 02How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?While not a mind-blowing move, it is good to see that the NeoPharm CO., LTD. ( KOSDAQ:092730 ) share price has gained...
分析記事 • Feb 18We're Watching These Trends At NeoPharm (KOSDAQ:092730)What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
分析記事 • Feb 08We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory EarningsIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...
分析記事 • Jan 26NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend StockCould NeoPharm CO., LTD. ( KOSDAQ:092730 ) be an attractive dividend share to own for the long haul? Investors are...
分析記事 • Jan 15An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% UndervaluedDoes the January share price for NeoPharm CO., LTD. ( KOSDAQ:092730 ) reflect what it's really worth? Today, we will...
Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩34,000, the stock is trading at a trailing P/E ratio of 14.2x, up from the previous P/E ratio of 12.1x. This compares to an average P/E of 36x in the Personal Products industry in South Korea. Total return to shareholders over the past three years is a loss of 28%.
Is New 90 Day High Low • Jan 08New 90-day high: ₩29,500The company is up 2.0% from its price of ₩28,800 on 08 October 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩49,095 per share.
分析記事 • Jan 04Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?It is hard to get excited after looking at NeoPharm's (KOSDAQ:092730) recent performance, when its stock has declined...
分析記事 • Dec 24NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend SoonReaders hoping to buy NeoPharm CO., LTD. ( KOSDAQ:092730 ) for its dividend will need to make their move shortly, as...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩750 Per ShareWill be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.7% is in the top quartile of South Korean dividend payers (2.6%), and it is higher than industry peers (0.6%).
分析記事 • Dec 15What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?NeoPharm CO., LTD. ( KOSDAQ:092730 ), is not the largest company out there, but it maintained its current share price...
分析記事 • Dec 04Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Nov 23Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...
Major Estimate Revision • Nov 11Analysts lower EPS estimates to ₩2,091The 2020 consensus revenue estimate was lowered from ₩85.3m to ₩82.0m. Earning per share (EPS) estimate was also lowered from ₩2,326 to ₩2,091 for the same period. Net income is expected to shrink by 5.9% next year compared to 61% growth forecast for the Personal Products industry in South Korea . The consensus price target was lowered from ₩44,250 to ₩42,500. Share price is up 5.9% to ₩28,850 over the past week.
Is New 90 Day High Low • Sep 24New 90-day low: ₩27,250The company is down 18% from its price of ₩33,150 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩47,836 per share.